Mouse Anti-GUCY2C Recombinant Antibody (1E1) (CBMAB-G0938-LY)

Name: Mouse Anti-GUCY2C Recombinant Antibody (1E1)
SKU: CBMAB-G0938-LY
Rating: 5 (1 reviews)

See all GUCY2C antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

1E1

Application

Immunogen

GUCY2C (-, 24 a.a. ~ 133 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K

Specificity

Human

Antibody Isotype

IgG2b, κ

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

guanylate cyclase 2C (heat stable enterotoxin receptor)

Introduction

This gene encodes a transmembrane protein that functions as a receptor for endogenous peptides guanylin and uroguanylin, and the heat-stable E. coli enterotoxin. The encoded protein activates the cystic fibrosis transmembrane conductance regulator. Mutations in this gene are associated with familial diarrhea (autosomal dominant) and meconium ileus (autosomal recessive). [provided by RefSeq, Nov 2016]

Entrez Gene ID

2984

UniProt ID

P25092

Alternative Names

Guanylate Cyclase 2C; STA Receptor; Intestinal Guanylate Cyclase; Guanylyl Cyclase C; EC 4.6.1.2; GUC2C; STAR; GC-C; Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor);

Function

Guanylyl cyclase that catalyzes synthesis of cyclic GMP (cGMP) from GTP (PubMed:1718270, PubMed:11950846, PubMed:23269669, PubMed:22521417, PubMed:22436048).

Receptor for the E.coli heat-stable enterotoxin; E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GUCY2C (PubMed:1718270, PubMed:1680854).

Also activated by the endogenous peptides guanylin and uroguanylin (PubMed:8381596).

Biological Process

cGMP biosynthetic process Source: GO_Central
Intracellular signal transduction Source: InterPro
Receptor guanylyl cyclase signaling pathway Source: GO_Central
Regulation of cell population proliferation Source: Ensembl
Response to toxic substance Source: Ensembl
Signal transduction Source: GO_Central

Cellular Location

Cell membrane; Endoplasmic reticulum membrane. The 145 kDa plasma membrane form of GUCY2C contains sialic acid and galactose residues, while a differencially glycosylated 130 Kda form is a high mannose form that is resident in the endoplasmic reticulum and may serve as the precursor for the cell surface form.

Involvement in disease

Diarrhea 6 (DIAR6):
A relatively mild, early-onset chronic diarrhea that may be associated with increased susceptibility to inflammatory bowel disease, small bowel obstruction, and esophagitis.
Meconium ileus (MECIL):
A condition characterized by intestinal obstruction due to inspissated meconium in the distal ileum and cecum, which develops in utero and presents shortly after birth as a failure to pass meconium. Meconium ileus is a known clinical manifestation of cystic fibrosis.

Topology

Extracellular: 24-430
Helical: 431-454
Cytoplasmic: 455-1073

PTM

Glycosylation at Asn-75 and/or Asn-79 is required for interaction with VIP36 while glycosylation at Asn-345 and Asn-402 modulates ligand-mediated GUCY2C activation.

Barton, J. R., Londregran, A. K., Alexander, T. D., Entezari, A. A., Bar-Ad, S., Cheng, L., ... & Waldman, S. A. (2023). Intestinal neuropod cell GUCY2C regulates visceral pain. The Journal of Clinical Investigation, 133(4).

Rappaport, J. A., Entezari, A. A., Caspi, A., Caksa, S., Jhaveri, A. V., Stanek, T. J., ... & Waldman, S. A. (2022). A β-catenin-TCF-sensitive locus control region mediates GUCY2C ligand loss in colorectal cancer. Cellular and Molecular Gastroenterology and Hepatology, 13(4), 1276-1296.

Lisby, A. N., Flickinger Jr, J. C., Bashir, B., Weindorfer, M., Shelukar, S., Crutcher, M., ... & Waldman, S. A. (2021). GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert review of precision medicine and drug development, 6(2), 117-129.

Mishra, V., Bose, A., Kiran, S., Banerjee, S., Shah, I. A., Chaukimath, P., ... & Visweswariah, S. S. (2021). Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C. Journal of Experimental Medicine, 218(11).

van Vugt, A. H., Bijvelds, M. J., de Jonge, H. R., Meijsen, K. F., Restin, T., Bryant, M. B., ... & Middendorp, S. (2021). A potential treatment of congenital sodium diarrhea in patients with activating GUCY2C mutations. Clinical and Translational Gastroenterology, 12(11).

Jimenez-Luna, C., González-Flores, E., Ortiz, R., Martínez-González, L. J., Antúnez-Rodríguez, A., Expósito-Ruiz, M., ... & Prados, J. (2021). Circulating PTGS2, JAG1, GUCY2C and PGF mRNA in peripheral blood and serum as potential biomarkers for patients with metastatic colon cancer. Journal of Clinical Medicine, 10(11), 2248.

Mathur, D., Root, A. R., Bugaj-Gaweda, B., Bisulco, S., Tan, X., Fang, W., ... & Sapra, P. (2020). A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal CancersA GUCY2C-CD3 Bispecific Targets Gastrointestinal Cancers. Clinical Cancer Research, 26(9), 2188-2202.

Snook, A. E., Baybutt, T. R., Xiang, B., Abraham, T. S., Flickinger, J. C., Hyslop, T., ... & Waldman, S. A. (2019). Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. Journal for ImmunoTherapy of Cancer, 7(1), 1-12.

Merlino, D. J., Barton, J. R., Charsar, B. A., Byrne, M. D., Rappaport, J. A., Smeyne, R. J., ... & Waldman, S. A. (2019). Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin. Brain Structure and Function, 224, 2983-2999.

Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger Jr, J. C., Ridge, N. A., Marszalowicz, G. P., ... & Snook, A. E. (2018). Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer immunology research, 6(5), 509-516.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-GUCY2C Recombinant Antibody (1E1)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-GUCY2C Recombinant Antibody (3D5) (CAT#: CBMAB-G5791-LY)

Mouse Anti-GUCY2C Recombinant Antibody (1B11) (CAT#: CBMAB-G5784-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry